Transforming Growth Factor-β (TGF-β) and Epidermal Growth Factor (EGF) signaling pathways are both independently implicated as key regulators in tumor formation and progression. Here, we report that the tumor-associated overexpression of epidermal growth factor receptor (EGFR) desensitizes TGF-β signaling and its cytostatic regulation through specific and persistent Stat3 activation and Smad7 induction in vivo. In human tumor cell lines, reduction of TGF-β-mediated Smad2 phosphorylation, nuclear translocation and Stat3 target gene activation were observed when EGFR was overexpressed, but not in cells that expressed EGFR at normal levels. We identified Stat3, which is activated specifically and persistently by overexpressed EGFR, as a key signaling molecule responsible for the reduced TGF-β sensitivity. Stable knockdown of Stat3 using small hairpin RNA (shRNA) in Head and Neck (HNS) and Epidermoid (A431) tumor cell lines resulted in reduced growth compared with control shRNA-transfected cells when grown as subcutaneous tumor xenografts. Furthermore, xenografts with Stat3 knockdown displayed increased Smad3 transcriptional activity, increased Smad2 phosphorylation and decreased Smad7 expression compared with control xenografts in vivo. Consistently, Stat3 mRNA and protein expression was also significantly reduced when EGFR activity was blocked by a specific tyrosine kinase inhibitor, AG1478, or in Stat3 knockdown tumors. Similarly, Smad7 knockdown also resulted in enhanced Smad3 transcriptional activity in vivo. Importantly, there was no uptake of subcutaneous HNS xenografts with Smad7 knockdown. Taken together, we demonstrate here that targeting Stat3 or Smad7 for knockdown results in resensitization of TGF-β signaling axis driving tumor growth, which can be targeted therapeutically.

Oncogene (2013) 32, 2433–2441; doi:10.1038/onc.2012.260; published online 2 July 2012

Keywords: EGFR; TGF-β; Stat3; Smad7; cancer

INTRODUCTION

Growth factor and cytokine signaling networks control many aspects of cell behavior such as proliferation, survival, migration, invasive capabilities, transformation and differentiation. In normal cells, these complex signaling pathways are tightly regulated. Alterations of these signals are often found to cause, directly or indirectly, tumor formation. Transforming Growth Factor-β (TGF-β) and Epidermal Growth Factor (EGF) signaling pathways are both independently implicated as key regulators in tumor formation, and as such are potential therapeutic targets.

TGF-β regulates a wide range of cellular processes including cell proliferation, differentiation, migration, organization and death. It is widely accepted that TGF-β can act as a tumor suppressor, given the frequent occurrence of tumor formation when TGF-β or its downstream signaling is disrupted by gene targeting in mice or the identification of loss-of-function mutations within several TGF-β signaling components in many types of human cancers. Biological responses to TGF-β are mediated mainly by the type I (TβRⅠ) and II (TβRⅡ) transmembrane cell surface receptors, which contain cytoplasmic domains with serine/threonine kinase activity. The activated ligand–receptor complex then binds and phosphorylates, through TβRⅠ, the intracellular signaling molecules Smad2 and Smad3. Once phosphorylated, these regulatory Smads (R-Smads) form complexes with Smad4 (also called DPC4 for deleted in pancreatic carcinoma locus 4) and translocate into the nucleus. In the nucleus, they associate with transcription factors to form transcriptionally active DNA complexes.

TGF-β signaling can be negatively regulated by multiple proteins located both extracellularly and intracellularly, including Smad7, which directly competes with Smad2/3 for binding to TβRⅠ. Perturbation of TGF-β signaling by Smad7 as a transgene leads to various forms of tumor formation in mice. However, it remains to be answered whether the TGF-β signaling pathway is so fundamental in maintaining homeostasis that not only its direct disruptions but also other oncogenic signals acting through the impairment of TGF-β signaling leads to tumor formation.

Epidermal growth factor receptor (EGFR) signaling is elicited by ligand binding, initiating the activation of many downstream signaling cascades including the following: Ras-Raf-Erk1/2, Phospholipase Cγ, the PTEN-regulated phosphatidylinositol 3-kinase (PI3-K)-Akt-mTOR, Src and Signal transducer and activator of transcription (Stat) family members. In turn, these signaling intermediates trigger gene transcription of numerous proteins involved in regulating a variety of cellular functions. Not surprisingly, genetic alterations leading to EGFR overexpression or mutation are frequently observed in almost all epithelial cancer types. However, which downstream molecules are specifically activated by tumor-associated and overexpressed EGFR and are responsible for EGFR’s tumorigenic function have yet to be clearly identified.

1Department of Surgery, University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, Australia; 2Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran; and 3Australian Prostate Cancer Research Centre, Epworth Hospital, Richmond, VIC, Australia. Correspondence: Dr H-J Zhu, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, Victoria 3050, Australia.

E-mail: hongjian@unimelb.edu.au

Received 14 February 2012; revised 17 April 2012; accepted 1 May 2012; published online 2 July 2012
Stat3 is a member of the Stat family of cytoplasmic transcription factors that are activated by many cytokine and growth factor receptors including the EGFR. Phosphorylated Stat3 transmits its signal from the EGFR to the nucleus, where it initiates transcription of multiple genes known to promote cancer development. Indeed, Stat3 activation has been detected at a high frequency in many types of tumors, and its activity is required for the growth of head-and-neck cancer and multiple myeloma cells. We have recently discovered that persistent activation of Stat3 causes 100% occurrence of tumor formation in a genetic mouse model. Importantly, this study identified that only persistent, not transient, activation of Stat3 desensitizes TGF-β signaling via increased Stat3-mediated Smad7 expression, releasing cells from its cytotatic regulation, thereby allowing tumor formation.

Here we establish a novel EGFR–Stat3–Smad7–TGF-β signaling molecular axis where tumor-associated overexpression of EGFR in epithelial cells results in sustained hyperactivation of Stat3, which induces Smad7 expression, compromising TGF-β’s cytotatic regulation of the epithelium and consequent tumor formation and growth.

RESULTS

Overexpression of EGFR inhibits TGF-β signaling

Previously, we found that aberrant IL-6/gp130 signaling causes the desensitization of TGF-β signaling in the gastric epithelium. To test the effect of EGFR signaling on TGF-β signaling, seven human cell lines with varying EGFR expression levels were used (Figure 1a). Of those, A431, HNS, 293T-EGFR and U87MG-EGFR overexpress EGFR, whereas the 293T, A549 and U87MG do not. The Smad3 luciferase reporter construct pCAGA12-luc was transiently transfected into those cell lines to quantitatively determine TGF-β signaling sensitivity. Stimulation with TGF-β-activated pCAGA12-luc activity was seen in all seven cell lines used (Figure 1b). Interestingly, this increased pCAGA12-luc activity was significantly reduced in all four EGFR-overexpressing cells, but not in the low levels of EGFR-expressing cells when cells were cotreated with EGF (Figure 1b), suggesting that EGF inhibited pCAGA12-luc activity in cells with high levels of EGFR expression. Furthermore, EGF reduced the TGF-β-mediated phospho-Smad2 levels in the EGFR-overexpressing cell lines A431, HNS (Figure 1c) and 293T-EGFR cells (Supplementary Figure 1A), without affecting phospho-Smad2 levels in normal EGFR-expressing cells (293T and A549; Supplementary Figure 1A). Consequently, EGF treatment caused a marked decrease of Smad2 nuclear localization by TGF-β signaling in A431 cells (Figure 1d). In addition, EGF reduced the expression of TGF-β-induced p21WAF1, an inhibitor of cyclin-dependent kinases and mediator of growth arrest (Supplementary Figure 1B).

To confirm that EGFR activation was responsible for the observed desensitization of the TGF-β signaling, AG1478, a specific inhibitor of EGFR , was used. EGFR-mediated reduction of the TGF-β reporter activity was reversed when A431 and HNS cells were cotreated with AG1478 (Figure 1e), confirming that activation of overexpressed EGFR mediates the desensitization of the TGF-β signaling. Furthermore, blockade of EGFR activity in HNS cells by AG1478 reestablished these cells to the growth-inhibitory effects of TGF-β, producing a reduction in [3H]-thymidine incorporation > 50% (Figure 1f).

EGF-mediated inhibition of TGF-β signaling is not dependent on PI3-K and MEK activity

The two most documented signaling pathways activated upon EGFR phosphorylation are the Ras-MAPKs (MEKs) and the PI3K/Akt pathways. Both pathways have been implicated in modulating Smad activity. To examine whether these pathways were involved in the desensitization of TGF-β signaling by overexpressed EGFR, we used pharmacological inhibitors to block either MEK (U0126) or PI3-K (LY294002) activity without affecting phospho-EGFR levels (Figures 2a and b; Supplementary Figures 2A and B). Unlike the EGFR inhibitor AG1478, neither U0126 nor LY294002 reestablished the TGF-β reporter activity in HNS and 293T-EGFR cells (Figure 2c and Supplementary Figure 2C), suggesting that the inhibition of the TGF-β pathway mediated by the overexpression of EGFR is not dependent on MEK and PI3K signaling.

EGF overexpression induces specifically sustained Stat3 phosphorylation and transcriptional activity

As we had previously shown that sustained Stat3 activation results in the desensitization of TGF-β signaling in the IL-6/gp130 signaling system, we next set out to determine whether EGFR activated Stat3 in several human cell lines. Although EGF stimulation resulted in increased phospho-EGFR, phospho-Erk1/2 and phospho-Akt levels in all five cell lines used, phosphorylation of Stat3 was only observed in cell lines overexpressing EGFR (A431, HNS and 293T-EGFR) (Figure 3a). Furthermore, this EGFR-overexpression-specific Stat3 activation was sustained for at least 8 h post EGF stimulation (Figure 3b). In fact, the EGFR-mediated Stat3 phosphorylation observed correlated with an increase in Stat3 transcriptional activity as measured by the luciferase activity using the pAPRE-luc reporter construct in EGFR-overexpressing cells (Supplementary Figures 3A and B). TGF-β stimulation did not affect EGFR-mediated Stat3 activity (Supplementary Figure 3C). There was minimal Stat3 reporter activation (< twofold) in the cells expressing normal or low levels of EGFR (293T, A549 and U87MG; Supplementary Figure 3B). Taken together, these results demonstrate that overexpression of EGFR mediates specifically sustained Stat3 phosphorylation and transcriptional activity.

Our results so far demonstrate an inverse correlation between the specific activation of Stat3 and the TGF-β signaling sensitivity specifically in cells overexpressing EGFR. To verify conclusively that Stat3 mediates desensitization of the TGF-β signaling, we knocked down Stat3 protein expression by small interfering RNA (siRNA) (Supplementary Figure 4A). The activity of the TGF-β reporter pCAGA12-luc was increased when the endogenous Stat3 levels were knocked down in both A431 and HNS cells (Figure 4c), indicating that Stat3 is indeed required for the overexpressed EGFR-mediated desensitization of the TGF-β signaling. Importantly, Stat3 knockdown restored TGF-β-mediated growth suppression of HNS cells (Figure 4d).

Stable knockdown of Stat3 in HNS and A431 cells results in reduced tumor growth

To confirm our in vitro results and to examine the role of Stat3 in an in vivo setting, we generated HNS and A431 cells with stable knockdown of Stat3 expression using Stat3-specific small hairpin RNA (shRNA). HNS and A431 cells with reduced Stat3 expression (designated S1, S2 and S3 for HNS and A-S1 and A-S2 for A431 cells) expressed similar levels of EGFR compared with control cells (Figure 4a and Supplementary Figure 4B). As expected, S1, S2 and S3 cells also displayed reduced EGFR-mediated Stat3 transcriptional activity (Supplementary Figure 4C) and phosphorylated Stat3 compared with the control HNS cell line, although no effect was seen on phosphorylated EGFR or phospho-Erk1/2 levels (Supplementary Figure 4D). Most importantly, the tumor growth of these clones was significantly reduced when grown as xenografts in BALB/c nu/nu mice, indicating a key role of Stat3 in mediating tumorigenesis of HNS and A431 cells (Figure 4b and Supplementary Figure 4B). Two tumors from each HNS subclone were removed with subsequent western blot analysis of these tumors, showing that the knockdown of Stat3 had remained intact in vivo throughout the course of the experiment (Supplementary

Oncogene (2013) 2433 – 2441
Figure 1. Overexpression of EGFR desensitizes the TGF-β pathway. (a) Cell lines as indicated were lysed and examined for EGFR and Actin protein expression or (b) transfected with the Smad3 reporter construct pCAGA12-luc and allowed to adhere overnight. Cells were then treated with 2 ng/ml of TGF-β in the presence (●) or absence (■) of EGF (20 ng/ml) for a further 24 h, and then lysed and assessed for luciferase activity. Data are expressed as relative Smad3 luciferase activity (fold change) by standardizing the luciferase activity of unstimulated cells to 1, and accordingly normalizing all other raw values. (c) Cells were treated with EGF (20 ng/ml) overnight, then stimulated with TGF-β (0, 0.2 and 2 ng/ml) for 30 min and lysed and examined for phospho-Smad2 and total Smad2 expression. (d) A431 cells were stimulated with or without EGF (20 ng/ml) overnight, then treated with or without TGF-β (0.2 ng/ml) for 15 min. Cells were then fixed in formaldehyde, permeabilized in 0.2% Triton-X-100 and stained with anti-Smad2 antibody. Localization of Smad2 was visualized with Alexa488-conjugated secondary antibody using confocal microscopy. (e) A431 (i) and HN5 (ii) cells were transfected with pCAGA12-luc, pretreated with (■) or without (●) AG1478 for 4 h, and then stimulated with TGF-β (2 ng/ml) and/or EGF (20 ng/ml) for a further 24 h. Cells were then lysed and assessed for luciferase activity and expressed as outlined in Figure 1b. (f) HN5 cells were treated with or without TGF-β in the presence (●) or absence (■) of AG1478 for 48 h. Cells were then incubated with 0.2 μCi of [3H]-thymidine/well for 4 h, lysed with 0.5 M NaOH, harvested and then measured for incorporated [3H]-thymidine.

Figure 2. EGF-mediated desensitization of the TGF-β pathway is MEK and PI3K independent. HN5 cells were treated with (a) U0126 (0, 2 and 10 μM) or (b) LY294002 (0, 2 and 10 μM) for 4 h, then stimulated with or without EGF (20 ng/ml) for 10 min. Cells were then lysed and examined for phosphorylated and total expression of EGFR, Akt and Erk1/2. (c) HN5 cells were transfected with pCAGA12-luc, pre-treated with (■) or without (●) U0126 and (ii). LY294002 for 4 h, then stimulated with TGF-β (2 ng/ml) and/or EGF (20 ng/ml) for a further 24 h. Cells were then lysed and assessed for luciferase activity and expressed as outlined in Figure 1b.
Figure 3. Overexpression of the EGFR leads to sustained Stat3 phosphorylation and desensitized TGF-β signaling. Cells were stimulated with or without EGF (20 ng/ml) for (a) 10 min or (b) 0.2, 1, 2, 4 and 8 h and then lysed and examined for phosphorylated and total expression of EGFR, Stat3, Akt and Erk1/2. (c) At 24 h following transient transfection with pCAGA12-luc, A431 (i) and HN5 (ii) cells were retransfected with control (□) or Stat3 (■) siRNA, seeded and allowed to adhere for 24 h. Cells were then stimulated with TGF-β (2 ng/ml) ± EGF (20 ng/ml) as indicated above for a further 24 h. Cells were then lysed and assessed for luciferase activity and expressed as relative luciferase activity (fold change). (d) Following transient transfection with control (□) or Stat3 (■) siRNA, HN5 cells were seeded and allowed to adhere overnight. Cells were then treated with or without TGF-β for 48 h and measured for incorporated [3H]-thymidine as outlined in Figure 1f.

Figure 4. Stable Stat3 knockdown desensitizes the TGF-β signaling pathway in vitro and in vivo. (a) HN5-control and Stat3 shRNA clones (S1, S2, S3) were lysed and examined for EGFR, Stat3 and Actin protein expression or (b) inoculated subcutaneously into both flanks of BALB/cnu-/- female mice and measured for tumor volume (n = 10/group) as indicated in Materials and methods; HN5-control (■) or Stat3 shRNA (open symbols). (c) HN5-control, S1, S2 and S3 cells were transfected with pCAGA12-luc and allowed to adhere overnight. Cells were then treated with 2 ng/ml of TGF-β in the presence (□) or absence (■) of EGF (20 ng/ml) for a further 24 h, and then either lysed and assessed for luciferase activity as outlined in Figure 1b or (d) inoculated subcutaneously into both flanks of BALB/cnu-/- female mice and analyzed for Smad3 reporter activity using the IVIS lumina Animal Imager as outlined in Materials and methods 24 h post inoculation. Cells were infected with the adenoviral smad3 reporter construct (Ad-pCAGA-luc) overnight, 24 h before inoculation into mice. Analysis of total photon emissions (Smad3 transcriptional activity) was performed using the IVIS lumina image analysis software and was presented relative to control tumors ± s.d. (n = 4). (e) HN5-control and Stat3 shRNA xenografts were removed and fixed in formaldehyde. Sections were stained for phospho-Smad2 expression and visualized with Alexa546-conjugated secondary antibody using confocal microscopy. Percentage positive staining was determined by counting approximately 3000 cells per group.
luciferase activity. Data are expressed as relative luciferase activity (fold change) as described in Figure 3c. (b) Cells were then stimulated with TGF-β as indicated above for a further 24 h. Cells were then lysed and assessed for luciferase activity and expressed as outlined in Figure 1b. HN5 cells were treated with or without AG1478 overnight and then analyzed for Smad7 (b) mRNA and (c) protein expression.

Figure 6. Stat3 knockdown desensitizes the TGF-β signaling pathway by reducing Smad7 expression. (a) At 24 h following transient transfection with pSmad7-luc, A431 and HN5 cells were re-transfected with control (■) or Stat3 (■) siRNA, seeded and allowed to adhere for 24 h. Cells were then lysed and examined for Smad7 and Actin expression. (c) HN5-control or Stat3 shRNA clones (S1, S2, S3) were lysed and analyzed for Stat3 (■) and Smad7 (■) mRNA expression. (d) HN5-control and Stat3 shRNA xenografts from Figure 4e were stained for Smad7 expression and visualized with Alexa488-conjugated secondary antibody using confocal microscopy. Percentage positive staining was determined by counting approximately 4000 cells per group. (e) At 24 h following transient transfection with pCAGA12-luc, HN5 cells were re-transfected with control (■) or Smad7 (■) siRNA, seeded and allowed to adhere for 24 h. Cells were then stimulated with TGF-β (2 ng/ml) ± EGF (20 ng/ml) as indicated above for a further 24 h. Cells were then lysed and assessed for luciferase activity. Data are expressed as relative luciferase activity (fold change) as described in Figure 3c. (f) Following transient transfection with control (■) or Smad7 (■) siRNA, HN5 cells were seeded and allowed to adhere overnight. Cells were then measured for incorporated [3H]-thymidine as outlined in Figure 1f. (g) HN5-control or Smad7 shRNA cells were infected with the adenoviral smad3 reporter construct (Ad-pCAGA-luc) and then inoculated subcutaneously into both flanks of BALB/c Cyc/Cyc female mice. Smad3 reporter activity was analyzed as outlined in Figure 4d (n = 4).

As with transient knockdown of Stat3, stable knockdown of Stat3 increased the TGF-β-mediated activity of pCAGA12-luc and circumvented the inhibitory effects of EGF stimulation (Figure 4c). Furthermore, pCAGA12-luc activity was also increased by approximately 10-fold in HN5 cells with stable Stat3 knockdown compared with control cells in vivo (Figure 4d), whereas phospho-Smad2 expression was detected in approximately 4% of HN5 cells with Stat3 knockdown versus 1% of HN5 control cells in vivo (Figure 4e). These data confirm that Stat3 is required for the overexpressed EGFR-mediated desensitization of the TGF-β signaling.

Smad7-dependent desensitization of TGF-β signaling by EGFR. As IL-6/gp130 signaling sustained Stat3 activation and induced the expression of the negative regulator of TGF-β signaling, Smad7,21 we next examined whether the EGFR-Stat3-mediated desensitization of TGF-β signaling is also dependent on Smad7. Indeed, blockade of EGFR activation by AG1478 significantly reduced Smad7 gene promoter activity in A431 and HN5 cells (Figure 5a), whereas EGF stimulation enhanced Smad7 promoter activity (Supplementary Figure 5A). AG1478 treatment also reduced Smad7 mRNA and protein levels in HN5 cells (Figures 5b and c). In addition, EGF inhibited TGF-β-mediated TGFβRI/Smad2 association presumably through Smad7’s well-recognized role of competing for TGFβRI binding (Supplementary Figure 5B). Furthermore, both Smad7 promoter activity and Smad7 protein expression were reduced when the Stat3 expression levels were knocked down transiently by siRNA (Figure 6a and b). Comparison of HN5 control and stable Stat3 knockdown xenografts also revealed reduced Smad7 mRNA expression (Figure 6c) and protein expression in vivo (Figure 6d). These
data demonstrate that upregulation of Smad7 protein levels in EGFR-overexpressing tumor cells is through Stat3-mediated Smad7 promoter activation. To determine whether EGFR-mediated desensitization of TGFB signaling is due to increased Smad7 expression, we use Smad7 siRNA to knock down its expression. Indeed, in HNS tumor cells, Smad7 knockdown largely restored the TGFB reporter activity when EGFR is activated by EGF treatment (Figure 6e). It is noteworthy that the reporter activity in the absence of EGF treatment is also vastly increased by Smad7 knockdown, confirming the effect of increased basal Smad7 expression in EGFR-overexpressing cells. Importantly, Smad7 knockdown, similar to Stat3 knockdown, restored HNS tumor cell growth inhibitory sensitivity to TGFB (Figure 6f).

Finally, and similar to stable knockdown of Stat3, Smad7 knockdown by shRNA in HNS cells resulted in increased pCAGAt2-luc activity by approximately 10-fold compared with control cells in vivo (Figure 6g). Taken together, this signaling pathway cross talk mediated by EGFR-Stat3-Smad7-TGFB operates specifically in tumor-associated EGFR-overexpressing cells.

DISCUSSION

Ever since its discovery as one of the first receptor tyrosine kinases, EGFR and its signaling have been studied extensively. Many downstream pathways have been identified, but little is known about the difference between the normal and tumorigenic signals transduced from EGFR. It was presumed that the two main downstream pathways, Ras/MAPK and PI3-K/Akt, were responsible for EGFR-driven tumor growth. However, it has been difficult to detect the different mode of their activation between normal and tumor cells. At best, <10% elevation in MAPK activity by a constitutively active EGFR (Δ2-7EGRFR) was proposed to explain its tumorigenicity. Yet these downstream signals have been used to measure the efficacy of EGFR inhibition in cancer treatment.7–25 The identification of Stat3 here as a molecule specifically and persistently activated by the overexpressed and tumor-associated EGFR but not by EGFR expressed at normal levels reveals a critical signaling difference by EGFR between normal and tumor cells.

In both the normal and tumor cells, MAPK (Erk1/2) and Akt activation by EGFR are rapid and transient, regardless of the levels of EGFR expression. In contrast, low levels of EGFR do not activate Stat3, whereas only high levels of EGFR are capable of Stat3 activation. It appears that a threshold of approximately 106 EGFR/cell is required for EGFR-mediated Stat3 activity based on the cell lines tested here. Surprisingly, Stat3 activation by high levels of EGFR is slower than the Erk1/2 or Akt activation (Figure 3). Furthermore, the high level of EGFR-mediated Stat3 activation is persistent, unlike the transient nature of Erk1/2 and Akt activation. This is in direct contrast to cytokines such as IL-6 and IL-11, which mediated Stat3 activation rapidly and transiently.21,22 Our previous work demonstrated, in both animal models and human tissues, that persistent Stat3 activation leads to stomach epithelial hyperproliferation. It has become clear that Stat3 is an oncogene, and its activation is prevalent in many human cancers.16,31,32 However, unlike many other oncoproteins, there is no genetic evidence of gain-of-function mutation. Our observation that the tumor-associated overexpressed EGFR activates Stat3 persistently identifies EGFR as a physiologically relevant upstream molecular cause of Stat3 activation.

The tumorigenic consequence of the persistent Stat3 activation is at least partially mediated through the desensitization of TGFB signaling via its negative regulator Smad7 in stomach epithelium.27 Indeed, EGFR-mediated Stat3 activation also results in the desensitization of TGFB signaling in many tumor cell lines with EGFR overexpression. More importantly, in the head-and-neck tumor cell line with high levels of EGFR, HNS, there is a loss of cytosstatic/growth-inhibitory regulation by TGFB (Figure 1), which can be reversed by blocking either EGFR activation or reducing Stat3 or Smad7 expression (Figures 1, 3 and 6). Restoration of TGFB signaling as evident by enhanced cytosolic and nuclear phospho-Smad2 can also be achieved by stable knockdown of Stat3 or Smad7 expression in vivo (Figures 4 and 6).33 Thus, the loss of TGFB-cytostatic regulation on normal cell growth may represent a key molecular event during tumorigenesis driven by overexpression of EGFR through the EGFR-Stat3-Smad7-TGFB signaling axis.

Loss of TGFB sensitivity and thereby loss of cytosstatic regulation may represent a key molecular event in tumors. Desensitization to TGFB-mediated growth regulation can occur through the generation of loss-of-function mutations in either TGFB receptors or downstream signaling molecules.34 However, the overall occurrences of such mutations in human tumors are not frequent,34 suggesting that there may exist alternatives other than direct deletion or mutation of TGFB signaling components. Indeed, some early work showed that Ras inhibited TGFB signaling mediated by MAPK's modification of Smads,35,36 whereas IFN-y inhibits TGFB signaling through Stat1-mediated Smad7 expression.37 We have not seen any desensitization of TGFB signaling mediated by MAPKs (Erk1/2) in cells expressing high levels of EGFR (Figure 2). At least in the context of the stomach epithelium, Stat1 did not cause desensitization of TGFB signaling.21 We identify Stat3 as a key mediator of loss of TGFB-cytostatic regulation through signaling pathway cross talk in vivo both here and previously.21 In early tumor development where tumor growth and expansion are dominant, TGFB acts as a tumor suppressor, whereas it promotes invasion in late stages of tumor progression. Importantly, TGFB signaling may be necessary for the late tumor invasion, best demonstrated in colon tumor development where deletions or mutations in the TGFB signaling pathway gave rise to a better prognosis compared with patients with colon cancers with intact TGFB signaling.27,38 Desensitization of TGFB signaling through cross talk such as EGFR-Stat3-Smad7-TGFB demonstrated here, instead of the deletion or mutation of TGFB signaling, may enable the cells to bypass TGFB-tumor-suppressive effect in early tumor development, although the pathway can be repressed by different molecular means to promote tumor invasion at late stages.

Establishing the loss of cytosstatic regulation by TGFB signaling by tumor-associated EGFR overexpression through the EGFR-Stat3-Smad7-TGFB pathway axis has direct implications in EGFR signaling-targeted cancer therapy. First, it provides some clear molecular targets for treating EGFR-driven tumors, namely, Stat3 and Smad7. Several research groups have developed therapeutics that target Stat3 with some success,20,39,40 such as administration of antisense oligonucleotides targeting Stat3-expressing hematological tumors in mice39 and a synthesized tetrapienoid, CDDO-Imidazolide, to inhibit Stat3 phosphorylation in human myeloma and lung cancer cells.41 A similar strategy may be used to target Smad7 expression in tumors. A combination of Stat3 and/or Smad7 with EGFR targeting may provide a much more effective treatment. Second, to determine the efficacy of any EGFR-targeted treatment, in addition to its effects on Ras/MAPK and PI3-K/Akt pathways, it may be necessary to measure the effects on Stat3 activation, Smad7 expression and TGFB-signaling sensitivity. Given the availability of the sensitive luciferase reporters for Stat3, Smad7 and TGFB signaling, it is not unreasonable to envisage them being used to directly monitor the real effects of any EGFR-targeting therapy on its more specifically tumorigenic downstream signaling. More importantly, they can be used in vivo in real time when coupled with live imaging techniques to optimize treatment regimen, especially regarding dosages and schedules.
MATERIALS AND METHODS

Antibodies and reagents

Rabbit polyclonal antibodies directed against Erk1, TGF-βRI, p21WAF1 and Stat3 and the polyclonal goat Akt antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The phospho-Erk1/2, phospho-Stat3 and Phospho-Akt rabbit polyclonal antibodies were from Cell Signaling Technology (Danvers, MA, USA), whereas the mouse phospho-tyrosine monoclonal antibody (4G10) was from Upstate Biotechnology (Lake Placid, NY, USA). The anti-mouse Actin and Smad2 antibodies were purchased from Sigma (St Louis, MO, USA) and BD transfection reagents (Rockville, MD, USA). The anti-rabbit phospho-Smad2 antibody was kindly provided by Professor P Ten Dijke (Leiden University Medical Center, The Netherlands). The anti-rabbit Smad7 antibody was from Imgenex (Imgenex Corporation, San Diego, CA, USA). The anti-rabbit Alexa648-conjugated and Alexa488-conjugated secondary antibodies and the [3H]-thymidine were purchased from Invitrogen (Mulgrave, VIC, Australia). The mouse anti-EGF receptor antibody was provided by the Melbourne Centre for Clinical Sciences (Ludwig Institute for Cancer Research). AG1478 and Recombinant mouse EGF were kindly provided by the Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, and recombinant human TGF-β1 was purchased from R & D Systems (Minneapolis, MN, USA). The MEK inhibitor U0126 and the PI3K inhibitor LY294002 were purchased from Calbiochem (Merck KGaA, Darmstadt, Germany). Human Stat3 and Smad7 siRNAs were from Santa Cruz, whereas the fluorescein-labeled control siRNA was from Qiagen (Qiagen, SA Biosciences, Frederick, MD, USA).

Cells and cell culture

The epidermoid carcinoma cell line A431, the head-and-neck carcinoma cell line HN5, the human embryonic kidney cell line HEK-293 (293T) and the EGFR-Flag-tagged stably transfected HEK-293T-EGFR (293T-EGFR) cell line, the lung carcinoma cell line A549, the glioblastoma cell line U87MG and EGFR stable transfected U87MG-EGFR have all been previously described.42-46 The HN5-Stat3 shRNA clones (designated S1, S2 and S3) and A431-Stat3 shRNA clones (designated A-S1 and A-S2) were generated by transfecting cells with the SureSilencing Stat3-shRNA construct (Qiagen) using FuGENE6 DNA transfection reagent (Roche, Basel, Switzerland) following the manufacturer’s instructions, and selected for using Genetecin (Roche). Similarly, the HN5-Smad7 shRNA clones were generated by transfecting cells with the SureSilencing Smad7-shRNA construct (Qiagen) as above. Control HN5 cells were generated by stably transfecting a negative-control shRNA (Qiagen). All cells were maintained in Dulbecco’s Modified Eagle’s Medium containing 10% fetal bovine serum (FBS) (DKSH, Hallam, VIC, Australia), 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.2% Triton-X-100, 50 mM NaF, 2 mM MgCl2, 1 mM Na3VO4 and protease inhibitor cocktail (Roche). Cells were stimulated with or without TGF-β1 (20 ng/ml) and/or EGF (10 ng/ml), and allowed to adhere overnight. Quadruplicate wells were treated with TGF-β1 and/or EGF for 15 min. Cells were then washed twice in PBS, fixed in formaldehyde and permeabilized with PBS containing 0.2% Triton-X-100. Following blocking in PBS-Tween20 containing 5% BSA, cells were stained with anti-Smad2 antibody. Tumor xenografts were excised from mice at the end of the experiment and processed in 10% formalin/PBS before being embedded in paraffin. Tumor sections (4 µm) were then dewaxed, fixed, permeabilized and blocked as described above and stained with either pSmad2 or Smad7 antibody. Visualization was achieved with either Alexa488- or Alexa648-conjugated secondary antibody using confocal microscopy as described.49

Tumor growth and bioluminescence imaging in vivo

A431 cells were seeded on coverslips in six-well plates in DMEM-10% FBS and allowed to adhere overnight. Cells were transfected with or without EGF in serum-free media overnight, followed by treatment with TGF-β for 15 min. Cells were then washed twice in PBS, fixed in formaldehyde and permeabilized with PBS containing 0.2% Triton-X-100. Following blocking in PBS-Tween20 containing 5% BSA, cells were stained with anti-Smad2 antibody. Tumor xenografts were excised from mice at the end of the experiment and processed in 10% formalin/PBS before being embedded in paraffin. Tumor sections (4 µm) were then dewaxed, fixed, permeabilized and blocked as described above and stained with either pSmad2 or Smad7 antibody. Visualization was achieved with either Alexa488- or Alexa648-conjugated secondary antibody using confocal microscopy as described.49

Immunofluorescence staining and confocal microscopy

A431 cells were seeded onto coverslips in six-well plates in DMEM-10% FBS and allowed to adhere overnight. Cells were transfected with or without EGF in serum-free media overnight, followed by treatment with TGF-β for 15 min. Cells were then washed twice in PBS, fixed in formaldehyde and permeabilized with PBS containing 0.2% Triton-X-100. Following blocking in PBS-Tween20 containing 5% BSA, cells were stained with anti-Smad2 antibody. Tumor xenografts were excised from mice at the end of the experiment and processed in 10% formalin/PBS before being embedded in paraffin. Tumor sections (4 µm) were then dewaxed, fixed, permeabilized and blocked as described above and stained with either pSmad2 or Smad7 antibody. Visualization was achieved with either Alexa488- or Alexa648-conjugated secondary antibody using confocal microscopy as described.49

Western blot and immunoprecipitation analysis

Cells were lysed in a lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton-X-100, 50 mM NaF, 2 mM MgCl2, 1 mM NaVO4 and protease inhibitor cocktail (Roche)) and clarified by centrifugation (13,000 g, 15 min). Cell lysates were then separated by SDS-PAGE (Invitrogen), blotted onto nitrocellulose and probed with the indicated primary antibodies. The signal was visualized using the ECL chemoluminescence detection kit (GE Healthcare, Rydalmere, NSW, Australia) following incubation with appropriate secondary antibodies.

Luciferase assays

The firefly luciferase constructs pAPRE-luc,57 pSmad7-luc48 and pCAGA12-luc58 have all been previously described. Cells were transiently transfected with reporter constructs and an internal control (pRL-TK) using FuGENE HD transfection reagent (Roche), and evaluated 24-h after transfection period, cells were washed with PBS and cultured with TGF-β1, EGF, AG1478, U0126 and/or LY294002 at the concentrations indicated for a further 24 h. Cells were then lysed and assessed for luciferase activity using the Luciferase Reporter Assay Kit (Promega Corporation, Madison, WI, USA) following the manufacturer’s instructions. To assess the effects of Stat3 and Smad7 knockdown on Smad3 and Smad7 promoter activity, cells were transiently transfected with Stat3, Smad7 or fluorescein-labeled control siRNA using the HiPerFect transfection reagent (Qiagen) as per the manufacturer’s instructions 24 h after transfection with pCAGA12-luc and pSmad7-luc constructs. The creation of the Adenoviral Smad3 reporter (Ad-pCAGA12-luc) has been described previously.50

[3H]-thymidine incorporation assays

Cells were plated in 96-well plates in DMEM-10% FBS and allowed to adhere overnight. Quadruplicate wells were treated with TGF-β1 and/or AG1478 at the concentrations indicated for 48 h and then incubated with 0.2 µCi of [3H]-thymidine/well for an additional 4 h. Cells were lysed with 0.5 M NaOH, harvested using a Filtermate Harvester (Packard Instrument Co., Meriden, CT, USA) and the incorporated [3H]-thymidine measured with a Microplate Scintillation Counter (Packard Instrument Co.). To assess for the effects of Stat3 and Smad7 knockdown on [3H]-thymidine incorporation, cells were transiently transfected with Stat3, Smad7 siRNA or fluorescein-labeled control siRNA using the HiPerFect transfection reagent in solution and seeded in 96-well plates 24 h before TGF-β treatment. The bioluminescence images were recorded between 10 and 20 min after each D-luciferin injection, and analysis was performed using the ABI 7700 Real-Time PCR system software.

EGFR inhibits the TGF-β pathway

RB Luwor et al

Oncogene (2013) 2433 – 2441

© 2013 Macmillan Publishers Limited
CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This work was supported by grants from the National Health and Medical Research Council (NHMRC) to H-JZ. RBL is a recipient of the Winter and Glover Fellowship for Cancer Research from the University of Melbourne.

REFERENCES
1 Ettinger DS. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist 2006; 11: 358–373.
2 Jonissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284: 31–53.
3 Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003; 3: 807–821.
4 Zhu HJ, Burgess AW. Regulation of transforming growth factor-beta signalling. Mol Cell Biol Res Commun 2001; 4: 321–330.
5 Das P, Maduzia LL, Padgett RW. Genetic approaches to TGFbeta signalling pathways. Cytokine Growth Factor Rev 1999; 10: 179–186.
6 Luwor RB, Kaye AH, Zhu HJ. Transforming growth factor-beta (TGF-beta) and brain tumours. J Clin Neurosci 2008; 15: 845–855.
7 Sehgal PB. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol 2008; 19: 329–340.
8 Massague J, Chen YG. Controlling TGF-beta signalling. Genes Dev 2000; 14: 627–644.
9 Wrana JL. Regulation of Smad activity. Cell 2000; 100: 189–192.
10 Kuang C, Xiao Y, Liu X, Stringfeld TM, Zhang S, Wang Z et al. In vivo disruption of TGF-beta signalling by Smad7 leads to premature ductal lesions in the pancreas. Proc Natl Acad Sci USA 2006; 103: 1858–1863.
11 Burgess AW, EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008; 26: 263–274.
12 Grandal MV, Madhus H. Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. J Cell Mol Med 2008; 12: 1527–1534.
13 Engelman JA, Zeppulakh H, Mitsudomi T, Song Y, Hyland C, Park JD et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalling. Science 2007; 316: 1039–1043.
14 Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550–6556.
15 Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-receptor related peptides and their receptors in human malignancies. Crit Rev Oncol Hemotol 1995; 19: 183–232.
16 Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295–303.
17 Zhang Z, Wen Z, Damel JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264: 95–98.
18 Buettrn R, Mora LB, Jove R. Activated STAT signalling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945–954.
19 Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. Constitutive activation of Stat3 signalling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105–115.
20 Grandis JR, Drenting SD, Chakraborty A, Zhou MY, Zeng O, Pitt AS et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998; 102: 1385–1392.
21 Jenkins BJ, Grawl D, Nheu T, Najdovska M, Wang B, Waring P et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperplasia and desenstizes TGF-beta signalling. Nat Med 2005; 11: 845–852.
22 Nagane M, Narta Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK et al. Human glioblastoma xenografts expressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 2001; 95: 472–479.
23 Bakin AV, Tomlinson AK, Bhownick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J BioChem 2005; 270: 36803–36810.
24 Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/ Smad signalling by oncogenic Ras. Genes Dev 1999; 13: 804–816.
25 Remy L, Montmarquette A, Micchn SW. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 2004; 6: 358–365.
26 Montgomery RB, Moscatello DK, Wong AJ, Cooper JA, Stahl WL. Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 1995; 270: 30562–30566.
27 Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Saulea S, Anido J et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transfoming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001; 61: 6500–6510.
28 Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited anti-proliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316–2326.
29 Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancin M et al. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2006; 207: 420–427.
30 Tenney R, Stansfeld K, Pekala PH. Interleukin 11 signalling in 3T3-L1 adipocytes. J Cell Physiol 2005; 202: 160–166.
31 Haura EB, Turbsk J, Rove M. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2: 315–324.
32 Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 8017–8023.
33 Itman C, Small C, Griswold M, Nagara AK, Matzuk MM, Brown CW et al. Developomentally regulated SMAD2 and SMAD3 utilization directs activin signaling outcomes. Dev Dyn 2009; 238: 1688–1700.
34 Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signalling pathways in human cancer. Cytokine Growth Factor Rev 2006; 17: 41–58.
35 Howe PH, Dobrovolski SF, Reddy KB, Stacey DW. Release from G1 growth arrest by transforming growth factor beta 1 requires cellular ras activity. J Biol Chem 1993; 268: 21448–21452.
36 Ullora L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999; 397: 710–713.
37 Iacobetta BJ, Soong R, House AK, Hamelin R. Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFIR receptor, and BAX genes. J Pathol 1999; 187: 428–432.
38 Watanabe T, Wu TT, Catalano PJ, Ueki T, Satirano R, Haller DG et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196–1206.
39 Charle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623–629.
40 Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and inhibits apoptosis in myeloma and lung cancer cells. Clin Cancer Res 2006; 12(14 Pt 1): 4288–4293.
41 Plae AE, Sun N, Williams CR, Risingsong R, Honda T, Honda Y et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003; 9: 2798–2806.
42 Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signalling. J Biol Chem 1997; 272: 2927–2935.
43 Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or de2-7 EGFR inhibits the TGF-β pathway. RB Luwor et al. Mol Cancer Ther 2003; 2: 358–365.
its modulation by leukemia inhibitory factor. *J Biol Chem* 2000; 275: 25273–25285.

48 Brodin G, Ahgren A, ten Dijke P, Heldin CH, Heuchel R. Efficient TGF-beta induction of the Smad7 gene requires cooperation between AP-1, Sp1, and Smad proteins on the mouse Smad7 promoter. *J Biol Chem* 2000; 275: 29023–29030.

49 Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler S, Grail D et al. Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. *Mol Cell Biol* 2003; 23: 4371–4385.

50 Luwor RB, Wang B, Nheu TV, Iaria J, Tsantikos E, Hibbs ML et al. New reagents for improved in vitro and in vivo examination of TGF-beta signalling. *Growth Factors.* 29: 211–218.

51 Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. *Cancer Res* 1985; 45: 584–590.

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Author/s:
Luwor, RB; Baradaran, B; Taylor, LE; Iaria, J; Nheu, TV; Amiry, N; Hovens, CM; Wang, B; Kaye, AH; Zhu, H-J

Title:
Targeting Stat3 and Smad7 to restore TGF-beta cytostatic regulation of tumor cells in vitro and in vivo

Date:
2013-05-09

Citation:
Luwor, R. B., Baradaran, B., Taylor, L. E., Iaria, J., Nheu, T. V., Amiry, N., Hovens, C. M., Wang, B., Kaye, A. H. & Zhu, H.-J. (2013). Targeting Stat3 and Smad7 to restore TGF-beta cytostatic regulation of tumor cells in vitro and in vivo. ONCOGENE, 32 (19), pp.2433-2441. https://doi.org/10.1038/onc.2012.260.

Persistent Link:
http://hdl.handle.net/11343/264224

File Description:
Published version

License:
CC BY-NC-ND